CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


BLD-2660Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1428 MakAir Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment

BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9 that is selective over the cathepsins as well as other protease families, displays good metabolic stability and permeability, oral bioavailability and low cytochrome P450 (CYP) inhibition. It is under development for the treatment of coronavirus disease-19 (COVID-19) resulting from infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2), where there is significant unmet medical need.

NCT04334460 Sars-CoV2 Drug: BLD-2660

Primary Outcomes

Description: To evaluate time to recovery as defined by no longer requiring oxygen support or hospital discharge, whichever occurs first.

Measure: Time to recovery

Time: Course of study; 28 days

Description: To evaluate change in oxygenation in hospitalized adults with COVID-19 treated with BLD-2660. Measured by change from baseline to Day 10 or hospital discharge, if sooner, in the ratio of peripheral hemoglobin oxygen saturation to fraction of inspired oxygen (SpO2/FiO2)

Measure: Change in oxygenation

Time: 10 days

Secondary Outcomes

Description: To evaluate the safety and tolerability of BLD-2660 in the same population. Measured by incidence of TEAEs and serious adverse events (SAEs)

Measure: Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs)

Time: Course of study; 28 days

Description: To evaluate change in oxygenation while hospitalized & during follow-up visits. Measured by: Improvement from baseline to Days 10, 14, 21 and 28 as measured by the ratio of hemoglobin oxygen saturation to inspired oxygen fraction (SpO2/FiO2), categorized on the 4-point ordinal scale Time to discontinuation of oxygen supplementation requirement Mean SpO2 for subjects not requiring oxygen supplementation at Days 5, 10, 21 and 28 Number of O2 supplementation free days during hospitalization Proportion of subjects who do not require oxygen supplementation (sustained for at least 24 hours) during hospitalization

Measure: Change in oxygenation

Time: Course of study; 28 days

Other Outcomes

Description: Measured by mortality rate during the 28-day study period following enrollment.

Measure: Rate of mortality

Time: Course of study; 28 days

Description: Measured by time to discharge readiness

Measure: Time to discharge readiness

Time: Course of study; 28 days

Description: Measured by proportion of subjects ready to be discharged from the hospital during the 28-day study period following enrollment.

Measure: Proportion of subjects discharged during study

Time: Course of study; 28 days

Description: Measured by proportion of subjects with resolution of fever below entry criteria for 24 hours by Day 10 in subjects with fever at baseline

Measure: Proportion of subjects with resolved fever

Time: 10 days

Description: Measured by time to resolution of fever below entry criteria for 24 hours in subjects with fever at baseline

Measure: Time to resolution of fever

Time: Course of study; 28 days

Description: Measured by duration (in days) of remdesivir use in subjects starting remdesivir within 24 hours of first dose of BLD-2660

Measure: Duration of Remdesivir use

Time: Course of study; 28 days

Description: Measured by change from baseline to Days 10, 14, 21 and 28 in clinical status outcome using a 6-point ordinal scale

Measure: Change in clinical status

Time: Course of study; 28 days

Description: Measured by proportion of subjects reporting each 6-point ordinal scale of the clinical status outcome assessment.

Measure: Proportion of subjects in each category of the 6-point ordinal scale

Time: Course of study; 28 days

Description: Measured by change from baseline to Days 5, 10, 14, 21 and 28 in NEWS score

Measure: Change from in NEWS score

Time: Course of study; 28 days

Description: Measured by change from baseline to Days 10, 14, 21 and 28 in IL-6 in ng/mL measured by analytical assay

Measure: Change in IL-6

Time: Course of study; 28 days

Description: Measured by change from baseline to Days 10, 14, 21 and 28 in D-dimer in ng/mL measured by analytical assay

Measure: Change in D-dimer

Time: Course of study; 28 days


No related HPO nodes (Using clinical trials)